Definitive Contract 75N91019C00030
Award Date 9/11/19
Potential Completion Date 6/15/20
Potential Value $300K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
7
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed Similar Awards
- This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Heart, Lung and Blood Institute (NHLBI), a part of the National Institutes of Health (NIH), to Vala Sciences Inc. The $880,128 definitive cost-plus-fixed-fee contract is for the development of cell-based bioassays using induced pluripotent stem (iPS) cell lines. The goal is to provide research and development services related to assays and imaging systems for pharmaceutical testing. Vala Sciences has...
- This is a $1,937,903 firm fixed-price definitive contract awarded by the National Cancer Institute (NCI) to Vala Sciences Inc. on September 24, 2010. The contract is for research and development related to other sciences, with a period of performance ending on April 30, 2014. Vala Sciences is a for-profit company that provides products and services to help drug developers and researchers understand how human cells respond to drug compounds, including through the use of human induced...
- This federal contract award from the National Heart, Lung and Blood Institute (NHLBI) to Vala Sciences Inc., a small business, has a ceiling value of $159,401.00. The contract is for the Small Business Innovation Research (SBIR) Program Phase I, a research and development effort focused on biomedical (applied/exploratory) work. Vala Sciences Inc. has previously received prime federal contracts and grants from the National Cancer Institute, National Institute of Neurological Disorders and Stroke,...
- This is a $300,000.00 Firm Fixed Price Definitive Contract awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to Vala Sciences Inc. to conduct Small Business Innovation Research (SBIR) Phase I research and development on the "Development of Novel In-Vitro and In-Vivo Models to Support NeuroHIV Research." The contract was set aside for small businesses and has an ultimate completion date of September 26, 2025. Vala Sciences...
- This is a Phase II Small Business Innovation Research (SBIR) contract awarded by the National Cancer Institute (NCI), a civilian agency of the U.S. Department of Health and Human Services (HHS), to Nortis Inc., a for-profit manufacturer of biotechnology products and services. The contract, valued at $1,988,728.00, is for the development of a "vascularized tumor-microenvironment assay" to support the screening of anti-cancer drugs. This contract is designated as a Total Small Business...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The contract, valued at $299,937, was awarded to Vitan-Biotech LLC, a minority-owned for-profit biotechnology company, to develop single domain antibodies for the detection and imaging of modified RNA nucleosides. This research aligns with NCI's mission to advance...
- <p>The National Cancer Institute (NCI), a civilian federal agency, awarded a $1,416,758.40 Cost Plus Fixed Fee contract to Sensopath Technologies, Inc., a Woman Owned Small Business, for a Small Business Innovation Research (SBIR) Program Phase II action. The contract, which has a total small business set aside, was awarded on September 28, 2012 with an ultimate completion date of May 22, 2015. The contract delivers research and development services under the SBIR program.</p>
- This is a $399,062 firm-fixed-price SBIR Phase I contract awarded by the National Cancer Institute (NCI) to Avoneaux Medical Institute, LLC for the development of spatial micro-purification technology. The contract was set aside for small businesses and is part of the NCI's broader SBIR program, which funds research and development in support of the NIH and CDC's mission needs. The original solicitation sought proposals on a range of cancer-related topics, including alternatives to cell...
- <p>The National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Nanoscale Corporation for the development of a rapid in vitro screening assay to detect cancer biomarkers in urine and blood. The $150,000.00 firm-fixed-price contract has a completion date of May 2, 2013. This SBIR contract is part of the NCI's efforts to support small businesses in the development of innovative cancer-related technologies.</p>
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services (HHS). The $288,945 contract was awarded to Vascular Vision Pharmaceutical Co., a woman-owned small business, to conduct research on the topical delivery of nanoformulated bioactive chemopreventive agents for skin cancer. The work is being performed in Wynantskill, NY...